BackFate Therapeutics Overview

Fate Therapeutics Other Current Liabilities

Latest other current liabilities for FATE: $22M.

Get informed when a big investor buys or sells

+ Follow
Other Current Liabilities
$22.09M
69.62% YoYΔ $9.07M vs prior year quarter

Peer average

Loading

Fate Therapeutics Other Current Liabilities History

Loading

Fate Therapeutics vs. peers: Other Current Liabilities Comparison

Loading

Fate Therapeutics Other Current Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Fate Therapeutics (FATE) FAQ

Fate Therapeutics (FATE) currently reports a other current liabilities of $22M as of March 2026. That compares with $13M in the prior-year period — up 69.6% year over year. Use the charts on this page to explore Fate Therapeutics's other current liabilities history and peer comparisons.

Fate Therapeutics's other current liabilities increased from $13M to $22M — a 69.6% year-over-year increase (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Fate Therapeutics reported $22M in other current liabilities as of March 2026. That compares with $13M in the prior-year period — up 69.6% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current other current liabilities of $22M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Fate Therapeutics, and consider following FATE for alerts when major investors trade the stock.

Fate Therapeutics is classified in the Healthcare sector. On other current liabilities, it currently shows $22M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing FATE with unrelated industries.